ABSTRACT
This paper explores potential API loss mitigation during purification in recrystallization mother liquors, by including a resin adsorption step, to remove potential genotoxin impurities (PGTIs). Mometasone furoate (Meta) is used as model active pharmaceutical ingredient (API) in the presence of 4-dimethylaminopyridine (DMAP) and methyl p-toluenesulfonate (MPTS) as two model PGTIs. AG 50W-X2 and IRA68 resins efficiently removed DMAP and MPTS from methanol solutions, respectively, with adsorptions higher than 93% and Meta binding below 2%. Removal of GTIs using these resins sequentially, or combining them in a single step, was also assessed, with superior results for the later approach.
Abbreviations: API, active pharmaceutical ingredient; DMAP, 4-dimethylaminopyridine; DMAP-Me, methylated DMAP; GTI, potential genotoxin impurity; Meta, Mometasone furoate; MPTS, methyl p-toluenesulfonate; PTSA, p-toluenesulfonic acid; TTC, threshold of toxicological concern.
Supporting Information
Binding isotherm theoretical model parameters assessed in this report, pH influence on DMAP binding for several resins in water and in water:MeOH (1:1), kinetic profile of DMAP in water towards AG 50W-X2 resin and assessment of DMAP-ME and PTSA in Meta mother liquor by 1H NMR in MeOH-d4 can be found in Supporting Information.
Supplemental material
Supplemental data for this article can be accessed here.